Pluriomics’ Pluricyte® Cardiomyocytes selected by Wageningen University as model system to elucidate poorly understood methadone toxicity mechanisms

Leiden, The Netherlands, June 21th, 2017Pluriomics, an emerging Belgian/Dutch biotechnology company whose mission is to deliver cardiac drug discovery and safety solutions based on its best-in-class human iPSC-derived cardiomyocyte technology, today announced its Pluricyte® Cardiomyocytes were selected by the laboratory of Dr. Jochem Louisse from Wageningen University to evaluate in vitro cardiotoxic effect of methadone […]

READ MORE read more

Pluriomics BV partners with Pivot Park Screening Centre to offer ultra High Throughput Screening for Cardiovascular drug discovery services

Leiden and Oss, The Netherlands, May 30th, 2017Pluriomics and Pivot Park Screening Centre today announced a collaboration to improve Pluriomics’ cardiovascular drug discovery service offerings and to expand Pivot Park Screening Centre’s knowledge about new and innovative assay technologies used to accelerate drug discoveries. Giving Pluriomics access to the Screening Centre’s ultra High Throughput Screening […]

READ MORE read more

News archive

World Preclinical Congress 2017

Location: Boston, MA, USA Date: June 12 – 16, 2017 Pluriomics will attend World Preclinical Congress 2017 in Boston, MA, USA World Preclinical Congress (WPC) 2017 brings together chemists, biologists, pharmacologists, translational scientists and technology providers from academia and industry to discuss latest advances in preclinical drug discovery and development. As part of WPC 2017, the 10th annual […]

READ MORE read more

ISSCR 2017 Annual Meeting

Location: Boston, MA, USADate: June 14 – 17, 2017 Pluriomics will attend the ISSCR 2017 in Boston, MA, USA The ISSCR 2017 annual meeting brings together stem cell researchers from around the world to share their work, discuss tools, techniques, and the latest advances in stem cell science and regenerative medicine.  Don’t miss the opportunity […]

READ MORE read more

Events archive

About us

Pluriomics develops and commercializes fully functional, human iPSC-derived cardiomyocytes and provides high quality services for efficient and reliable safety pharmacology testing and cardiovascular drug efficacy screening.

Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human iPSC derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics combines Pluricyte® Cardiomyocytes with innovative technologies to develop in-house cell-based assays with the objective to improve drug safety and efficacy screening.

Read more

Pluricyte® Cardiomyocyte Kit

Pluricyte® Cardiomyocyte Kit is developed and manufactured for use in drug discovery and development. The kit includes both Pluricyte® Cardiomyocytes and Pluricyte® Cardiomyocyte Medium (serum-free).

iView product information

Our solutions